- Home
- TNGX vs MANH Comparison
TNGX vs MANH Comparison
Compare TNGX & MANH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- MANH
- Stock Information
- Founded
- TNGX 2014
- MANH 1990
- Country
- TNGX United States
- MANH United States
- Employees
- TNGX N/A
- MANH N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- MANH Computer Software: Prepackaged Software
- Sector
- TNGX Health Care
- MANH Technology
- Exchange
- TNGX Nasdaq
- MANH Nasdaq
- Market Cap
- TNGX 723.2M
- MANH 13.0B
- IPO Year
- TNGX N/A
- MANH 1998
- Fundamental
- Price
- TNGX $6.53
- MANH $216.10
- Analyst Decision
- TNGX Strong Buy
- MANH Buy
- Analyst Count
- TNGX 6
- MANH 9
- Target Price
- TNGX $10.00
- MANH $221.25
- AVG Volume (30 Days)
- TNGX 1.4M
- MANH 474.4K
- Earning Date
- TNGX 11-05-2025
- MANH 10-21-2025
- Dividend Yield
- TNGX N/A
- MANH N/A
- EPS Growth
- TNGX N/A
- MANH 9.17
- EPS
- TNGX N/A
- MANH 3.58
- Revenue
- TNGX $24,296,000.00
- MANH $1,057,690,000.00
- Revenue This Year
- TNGX $6.56
- MANH $5.15
- Revenue Next Year
- TNGX N/A
- MANH $6.66
- P/E Ratio
- TNGX N/A
- MANH $60.36
- Revenue Growth
- TNGX N/A
- MANH 6.13
- 52 Week Low
- TNGX $1.03
- MANH $140.81
- 52 Week High
- TNGX $10.85
- MANH $312.60
- Technical
- Relative Strength Index (RSI)
- TNGX 47.47
- MANH 52.45
- Support Level
- TNGX $6.25
- MANH $210.24
- Resistance Level
- TNGX $7.40
- MANH $220.31
- Average True Range (ATR)
- TNGX 0.40
- MANH 5.33
- MACD
- TNGX -0.06
- MANH -0.01
- Stochastic Oscillator
- TNGX 24.35
- MANH 76.68
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About MANH Manhattan Associates Inc.
Manhattan Associates provides software that helps users manage their supply chains, inventory, and omnichannel operations. Customers are generally retailers, wholesalers, manufacturers, and logistics providers. The company was founded in 1990 and serves more than 1,200 customers around the world.